Uveal Melanoma: A Review of Prognostic Factors for Metastases


Purpose of Review

In this article, we review the clinical and molecular prognostic factors for metastasis in uveal melanoma.

Recent Findings

Prognostic predictors for metastasis in uveal melanoma have evolved from utilizing clinical and histopathologic information to incorporating genetic data (e.g., gene expression profiling and chromosomal abnormality tests). Commercially available gene expression profiling and chromosomal abnormality tests have been validated to provide robust, reproducible prognostic information. Recently, the preferentially expressed antigen in melanoma (PRAME) has been identified as a biomarker for increased risk of metastasis, and the Cancer Genome Atlas (TCGA) Project has suggested four prognostic categories.


Prognostication of uveal melanoma informs patient management decisions in terms of appropriate intervals of surveillance screening and selection of high-risk patients appropriate for clinical trials. Understanding the factors involved in development of metastasis also helps elucidate potential biologic targets for therapeutics.

This is a preview of subscription content, access via your institution.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.

    Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011;118(9):1881–5. https://doi.org/10.1016/j.ophtha.2011.01.040.

    Article  PubMed  Google Scholar 

  2. 2.

    Network CGA. Genomic classification of cutaneous melanoma. Cell. 2015;161(7):1681–96. https://doi.org/10.1016/j.cell.2015.05.044.

    CAS  Article  Google Scholar 

  3. 3.

    Collaborative Ocular Melanoma Study Group. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch Ophthalmol. 2001; 119(5):670–676. https://doi.org/10.1001/archopht.119.5.670

  4. 4.

    Diener-West M, Reynolds SM, Agugliaro DJ, et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: collaborative ocular melanoma study group report no. 26. Arch Ophthalmol. 2005;123(12):1639–43. https://doi.org/10.1001/archopht.123.12.1639.

    Article  PubMed  Google Scholar 

  5. 5.

    • Yang J, Manson DK, Marr BP, Carvajal RD. Treatment of uveal melanoma: where are we now? Ther Adv Med Oncol. 2018; 10. https://doi.org/10.1177/1758834018757175. An extensive review of our growing knowledge of uveal melanoma biology and immunology and its application to developing novel targeted therapies.

  6. 6.

    Shields CL, Kaliki S, Furuta M, Mashayekhi A, Shields JA. Clinical spectrum and prognosis of uveal melanoma based on age at presentation in 8,033 cases. Retina (Philadelphia, Pa). 2012; 32(7):1363–1372. https://doi.org/10.1097/IAE.0b013e31824d09a8

  7. 7.

    Pogrzebielski A, Orłowska-Heitzman J, Romanowska-Dixon B. Uveal melanoma in young patients. Graefes Arch Clin Exp Ophthalmol. 2006;244(12):1646–9. https://doi.org/10.1007/s00417-006-0347-x.

    Article  PubMed  Google Scholar 

  8. 8.

    Singh AD, Shields CL, Shields JA, Sato T. Uveal melanoma in young patients. Arch Ophthalmol. 2000; 118(7):918–923. 10.1001/pubs.Ophthalmol.-ISSN-0003-9950-118-7-ecs80113.

  9. 9.

    Kaliki S, Shields CL, Mashayekhi A, Ganesh A, Furuta M, Shields JA. Influence of age on prognosis of young patients with uveal melanoma: a matched retrospective cohort study. Eur J Ophthalmol. 2013;23(2):208–16. https://doi.org/10.5301/ejo.5000200.

    Article  PubMed  Google Scholar 

  10. 10.

    • Fry MV, Augsburger JJ, Corrêa ZM. Clinical features, metastasis, and survival in patients younger than 21 years with posterior uveal melanoma. JAMA Ophthalmol. 2019; 137(1):75–81. https://doi.org/10.1001/jamaophthalmol.2018.5132. Retrospective study of patients younger than 21 years-old with posterior uveal melanoma suggesting young patients have equally bad, if not worse, prognosis.

  11. 11.

    Fry MV, Augsburger JJ, Hall J, Corrêa ZM. Posterior uveal melanoma in adolescents and children: current perspectives. Clin Ophthalmol. 2018;12:2205–12. https://doi.org/10.2147/OPTH.S142984.

    Article  PubMed  PubMed Central  Google Scholar 

  12. 12.

    Zloto O, Pe’er J, Frenkel S. Gender differences in clinical presentation and prognosis of uveal melanoma. Invest Ophthalmol Vis Sci. 2013;54(1):652–6. https://doi.org/10.1167/iovs.12-10365.

    Article  PubMed  Google Scholar 

  13. 13.

    Rietschel P, Panageas KS, Hanlon C, Patel A, Abramson DH, Chapman PB. Variates of survival in metastatic uveal melanoma. J Clin Oncol. 2005;23(31):8076–80. https://doi.org/10.1200/JCO.2005.02.6534.

    Article  PubMed  Google Scholar 

  14. 14.

    Park SJ, Oh C-M, Yeon B, Cho H, Park KH. Sex disparity in survival of patients with Uveal melanoma: better survival rates in women than in men in South Korea. Invest Ophthalmol Vis Sci. 2017;58(3):1909–15. https://doi.org/10.1167/iovs.16-20077.

    Article  PubMed  Google Scholar 

  15. 15.

    Andreoli MT, Mieler WF, Leiderman YI. Epidemiological trends in uveal melanoma. Br J Ophthalmol. 2015;99(11):1550–3. https://doi.org/10.1136/bjophthalmol-2015-306810.

    Article  PubMed  Google Scholar 

  16. 16.

    Gamel JW, McCurdy JB, McLean IW. A comparison of prognostic covariates for uveal melanoma. Invest Ophthalmol Vis Sci. 1992;33(6):1919–22.

    CAS  PubMed  Google Scholar 

  17. 17.

    Stålhammar G, See TR, Filì M, Seregard S. No gender differences in long-term survival after brachytherapy of 1,541 patients with uveal melanoma. Ocul Oncol Pathol. 2019;5(6):432–9. https://doi.org/10.1159/000497186.

    Article  PubMed  PubMed Central  Google Scholar 

  18. 18.

    • Corrêa ZM, Augsburger JJ. Independent prognostic significance of gene expression profile class and largest basal diameter of posterior Uveal melanomas. Am J Ophthalmol. 2016;162:20–27.e1. https://doi.org/10.1016/j.ajo.2015.11.019. A multivariate analysis demonstrating that gene expression profiling and largest basal diameter independently influenced risk for metastasis.

  19. 19.

    Factors predictive of growth and treatment of small choroidal melanoma: COMS Report No. 5. Arch Ophthalmol. 1997;115(12):1537–1544. https://doi.org/10.1001/archopht.1997.01100160707007

  20. 20.

    Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. Arch Ophthalmol. 2006; 124(12):1684–1693. https://doi.org/10.1001/archopht.124.12.1684

  21. 21.

    Hawkins BS. Collaborative ocular melanoma study group. The collaborative ocular melanoma study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma: IV. Ten-year mortality findings and prognostic factors. COMS report number 24. Am J Ophthalmol. 2004;138(6):936–51. https://doi.org/10.1016/j.ajo.2004.07.006.

    Article  PubMed  Google Scholar 

  22. 22.

    The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma II: initial mortality findings. COMS report no. 10. Am J Ophthalmol. 1998; 125(6):779–796. https://doi.org/10.1016/s0002-9394(98)00039-7

  23. 23.

    Shields CL, Furuta M, Thangappan A, Nagori S, Mashayekhi A, Lally DR, et al. Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch Ophthalmol. 2009;127(8):989–98. https://doi.org/10.1001/archophthalmol.2009.208.

    Article  PubMed  Google Scholar 

  24. 24.

    Damato B, Coupland SE. A reappraisal of the significance of largest basal diameter of posterior uveal melanoma. Eye. 2009;23(12):2152–62. https://doi.org/10.1038/eye.2009.235.

    CAS  Article  PubMed  Google Scholar 

  25. 25.

    Kujala E, Mäkitie T, Kivelä T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2003;44(11):4651–9. https://doi.org/10.1167/iovs.03-0538.

    Article  PubMed  Google Scholar 

  26. 26.

    Demirci H, Shields CL, Shields JA, Honavar SG, Eagle RC. Ring melanoma of the ciliary body: report on twenty-three patients. Retina (Philadelphia, Pa). 2002; 22(6):698–706; quiz 852-853. https://doi.org/10.1097/00006982-200212000-00003

  27. 27.

    Demirci H, Shields CL, Shields JA, Eagle RC, Honavar SG. Diffuse iris melanoma: a report of 25 cases. Ophthalmology. 2002;109(8):1553–60. https://doi.org/10.1016/s0161-6420(02)01104-1.

    Article  PubMed  Google Scholar 

  28. 28.

    Shields CL, Kaliki S, Furuta M, Shields JA. Diffuse versus nondiffuse small (≤ 3 MM thickness) choroidal melanoma: comparative analysis in 1,751 cases. The 2012 F. Phinizy Calhoun lecture. Retina (Philadelphia, Pa). 2013; 33(9):1763–1776. https://doi.org/10.1097/IAE.0b013e318285cd52

  29. 29.

    Walter SD, Chao DL, Feuer W, Schiffman J, Char DH, Harbour JW. Prognostic implications of tumor diameter in association with gene expression profile for uveal melanoma. JAMA Ophthalmol. 2016;134(7):734–40. https://doi.org/10.1001/jamaophthalmol.2016.0913.

    Article  PubMed  PubMed Central  Google Scholar 

  30. 30.

    • Demirci H, Niziol LM, Ozkurt Z, et al. Do largest basal tumor diameter and the American Joint Committee on Cancer’s Cancer Staging influence prognostication by gene expression profiling in choroidal melanoma. Am J Ophthalmol. 2018;195:83-92. https://doi.org/10.1016/j.ajo.2018.07.033. A multivariate analysis showing combining gene expression AJCC increases prognostication.

  31. 31.

    Pach JM, Robertson DM, Taney BS, Martin JA, Campbell RJ, O’Brien PC. Prognostic factors in choroidal and ciliary body melanomas with extrascleral extension. Am J Ophthalmol. 1986;101(3):325–31. https://doi.org/10.1016/0002-9394(86)90828-7.

    CAS  Article  PubMed  Google Scholar 

  32. 32.

    Gündüz K, Shields CL, Shields JA, Cater J, Brady L. Plaque radiotherapy for management of ciliary body and choroidal melanoma with extraocular extension. Am J Ophthalmol. 2000;130(1):97–102. https://doi.org/10.1016/s0002-9394(00)00385-8.

    Article  PubMed  Google Scholar 

  33. 33.

    Coupland SE, Campbell I, Damato B. Routes of extraocular extension of uveal melanoma: risk factors and influence on survival probability. Ophthalmology. 2008;115(10):1778–85. https://doi.org/10.1016/j.ophtha.2008.04.025.

    Article  PubMed  Google Scholar 

  34. 34.

    Shields CL, Kaliki S, Livesey M, Walker B, Garoon R, Bucci M, et al. Association of ocular and oculodermal melanocytosis with the rate of uveal melanoma metastasis: analysis of 7872 consecutive eyes. JAMA Ophthalmol. 2013;131(8):993–1003. https://doi.org/10.1001/jamaophthalmol.2013.129.

    Article  PubMed  Google Scholar 

  35. 35.

    Mashayekhi A, Kaliki S, Walker B, Park C, Sinha N, Kremer FZ, et al. Metastasis from uveal melanoma associated with congenital ocular melanocytosis: a matched study. Ophthalmology. 2013;120(7):1465–8. https://doi.org/10.1016/j.ophtha.2012.12.017.

    Article  PubMed  Google Scholar 

  36. 36.

    Shields CL, Kaliki S, Shah SU, Luo W, Furuta M, Shields JA. Iris melanoma: features and prognosis in 317 children and adults. J AAPOS. 2012;16(1):10–6. https://doi.org/10.1016/j.jaapos.2011.10.012.

    Article  PubMed  Google Scholar 

  37. 37.

    Augsburger JJ, Gamel JW. Clinical prognostic factors in patients with posterior uveal malignant melanoma. Cancer. 1990;66(7):1596–600. https://doi.org/10.1002/1097-0142(19901001)66:7<1596::aid-cncr2820660726>3.0.co;2-6.

    CAS  Article  PubMed  Google Scholar 

  38. 38.

    Seddon JM, Albert DM, Lavin PT, Robinson N. A prognostic factor study of disease-free interval and survival following enucleation for uveal melanoma. Arch Ophthalmol. 1983;101(12):1894–9. https://doi.org/10.1001/archopht.1983.01040020896012.

    CAS  Article  PubMed  Google Scholar 

  39. 39.

    Li W, Gragoudas ES, Egan KM. Metastatic melanoma death rates by anatomic site after proton beam irradiation for uveal melanoma. Arch Ophthalmol. 2000;118(8):1066–70. https://doi.org/10.1001/archopht.118.8.1066.

    CAS  Article  PubMed  Google Scholar 

  40. 40.

    Gündüz K, Shields CL, Shields JA, Cater J, Freire JE, Brady LW. Plaque radiotherapy of uveal melanoma with predominant ciliary body involvement. Arch Ophthalmol. 1999;117(2):170–7. https://doi.org/10.1001/archopht.117.2.170.

    Article  PubMed  Google Scholar 

  41. 41.

    • Amin M, Edge S, Greene F, et al, eds. AJCC Cancer Staging Manual. 8th ed. Springer; 2017. Updated staging system for posterior uveal melanoma. Largely unchanged from the 7th edition besides an added N subcategory to separate regional lymph node involvement from scattered tumor deposits localized in the orbit without lymph node involvement.

  42. 42.

    Simpson ER, Gallie BL, Saakyan S, Amiryan A, Finger PT, Chin KJ, et al. International validation of the American Joint Committee on Cancer’s 7th edition classification of uveal melanoma. JAMA Ophthalmol. 2015;133(4):376–83. https://doi.org/10.1001/jamaophthalmol.2014.5395.

    Article  Google Scholar 

  43. 43.

    Shields CL, Kaliki S, Furuta M, Fulco E, Alarcon C, Shields JA. American Joint Committee on Cancer classification of posterior uveal melanoma (tumor size category) predicts prognosis in 7731 patients. Ophthalmology. 2013;120(10):2066–71. https://doi.org/10.1016/j.ophtha.2013.03.012.

    Article  PubMed  Google Scholar 

  44. 44.

    Prescher G, Bornfeld N. Prognostic implications of monosomy 3 in uveal melanoma. Lancet. 1996;347(9010):1222.

    CAS  Article  Google Scholar 

  45. 45.

    Tschentscher F, Prescher G, Horsman DE, White VA, Rieder H, Anastassiou G, et al. Partial deletions of the long and short arm of chromosome 3 point to two tumor suppressor genes in uveal melanoma. Cancer Res. 2001;61(8):3439–42.

    CAS  PubMed  Google Scholar 

  46. 46.

    White VA, McNeil BK, Thiberville L, Horsman DE. Acquired homozygosity (isodisomy) of chromosome 3 during clonal evolution of a uveal melanoma: association with morphologic heterogeneity. Genes Chromosom Cancer. 1996;15(2):138–43. https://doi.org/10.1002/(SICI)1098-2264(199602)15:2<138::AID-GCC10>3.0.CO;2-J.

    CAS  Article  PubMed  Google Scholar 

  47. 47.

    Harbour JW, Onken MD, Roberson EDO, Duan S, Cao L, Worley LA, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science. 2010;330(6009):1410–3. https://doi.org/10.1126/science.1194472.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  48. 48.

    Damato B, Dopierala J, Klaasen A, van Dijk M, Sibbring J, Coupland SE. Multiplex ligation-dependent probe amplification of uveal melanoma: correlation with metastatic death. Invest Ophthalmol Vis Sci. 2009;50(7):3048–55. https://doi.org/10.1167/iovs.08-3165.

    Article  PubMed  Google Scholar 

  49. 49.

    Kilic E, Naus NC, van Gils W, Klaver CC, van Til ME, Verbiest MM, et al. Concurrent loss of chromosome arm 1p and chromosome 3 predicts a decreased disease-free survival in uveal melanoma patients. Invest Ophthalmol Vis Sci. 2005;46(7):2253–7. https://doi.org/10.1167/iovs.04-1460.

    Article  PubMed  Google Scholar 

  50. 50.

    Ehlers JP, Worley L, Onken MD, Harbour JW. Integrative genomic analysis of aneuploidy in uveal melanoma. Clin Cancer Res. 2008;14(1):115–22. https://doi.org/10.1158/1078-0432.CCR-07-1825.

    CAS  Article  PubMed  Google Scholar 

  51. 51.

    Onken MD, Worley LA, Ehlers JP, Harbour JW. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res. 2004;64(20):7205–9. https://doi.org/10.1158/0008-5472.CAN-04-1750.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  52. 52.

    Onken MD, Worley LA, Tuscan MD, Harbour JW. An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. J Mol Diagn. 2010;12(4):461–8. https://doi.org/10.2353/jmoldx.2010.090220.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  53. 53.

    Onken MD, Worley LA, Char DH, Augsburger JJ, Correa ZM, Nudleman E, et al. Collaborative ocular oncology group report no. 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology. 2012;119(8):1596–603. https://doi.org/10.1016/j.ophtha.2012.02.017.

    Article  PubMed  PubMed Central  Google Scholar 

  54. 54.

    Field MG, Harbour JW. Recent developments in prognostic and predictive testing in uveal melanoma. Curr Opin Ophthalmol. 2014;25(3):234–9. https://doi.org/10.1097/ICU.0000000000000051.

    Article  PubMed  PubMed Central  Google Scholar 

  55. 55.

    •• Field MG, Decatur CL, Kurtenbach S, et al. PRAME as an independent biomarker for metastasis in uveal melanoma. Clin Cancer Res. 2016; 22(5):1234–42. https://doi.org/10.1158/1078-0432.CCR-15-2071. Original study identifying PRAME as a biomarker of metastasis in Class 1 tumors, suggesting that PRAME expression will likely be a more accurate marker for metastasis than the Class 1A vs 1B division.

  56. 56.

    Ikeda H, Lethé B, Lehmann F, van Baren N, Baurain JF, de Smet C, et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity. 1997;6(2):199–208. https://doi.org/10.1016/S1074-7613(00)80426-4.

    CAS  Article  PubMed  Google Scholar 

  57. 57.

    Schefler AC, Koca E, Bernicker EH, Correa ZM. Relationship between clinical features, GEP class, and PRAME expression in uveal melanoma. Graefes Arch Clin Exp Ophthalmol. 2019;257(7):1541–5. https://doi.org/10.1007/s00417-019-04335-w.

    CAS  Article  PubMed  Google Scholar 

  58. 58.

    •• Robertson AG, Shih J, Yau C, et al. Integrative analysis identifies four molecular and clinical subsets in uveal melanoma. Cancer Cell. 2017; 32(2):204–20.e15. https://doi.org/10.1016/j.ccell.2017.07.003. Original study utilizing multiplatform molecular analysis of 80 uveal melanomas to identify four prognostic groups, creating a new subgroup in poor-prognosis monosomy 3 uveal melanoma.

  59. 59.

    Bakhoum MF, Esmaeli B. Molecular characteristics of uveal melanoma: insights from the Cancer Genome Atlas (TCGA) Project. Cancers (Basel). 2019; 11(8). https://doi.org/10.3390/cancers11081061

  60. 60.

    Jager MJ, Brouwer NJ, Esmaeli B. The Cancer Genome Atlas Project: an integrated molecular view of uveal melanoma. Ophthalmology. 2018;125(8):1139–42. https://doi.org/10.1016/j.ophtha.2018.03.011.

    Article  PubMed  Google Scholar 

  61. 61.

    Berry DE, Schefler AC, Seider MI, Materin M, Stinnett S, Mruthyunjaya P. Correlation of gene expression profile status and American Joint Commission on Cancer stage in uveal melanoma Retina Published online November 8, 2018. https://doi.org/10.1097/IAE.0000000000002385, 1.

Download references


This manuscript is partially supported by the Richard N and Marilyn K Witham Professorship, Todd Peters.

Author information



Corresponding author

Correspondence to Hakan Demirci.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Ocular Tumors

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Chang, E., Demirci, H. Uveal Melanoma: A Review of Prognostic Factors for Metastases. Curr Ophthalmol Rep 9, 1–6 (2021). https://doi.org/10.1007/s40135-020-00261-x

Download citation


  • Uveal melanoma
  • Ciliary body melanoma
  • Choroidal melanoma
  • Gene expression profiling
  • Metastasis
  • Prognosis